Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Human Respiratory Syncytial Virus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43893   clinical trials with a EudraCT protocol, of which   7300   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    21 result(s) found for: Human Respiratory Syncytial Virus. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2022-001981-36 Sponsor Protocol Number: 219238 Start Date*: 2022-11-15
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase 3, observer-blind, randomized, placebo controlled study to evaluate the non inferiority of the immune response and safety of the RSVPreF3 OA investigational vaccine in adults 50-59 years of...
    Medical condition: Respiratory syncytial virus infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10035732 Pneumonia respiratory syncytial viral PT
    21.1 10021881 - Infections and infestations 10038718 Respiratory syncytial virus bronchiolitis PT
    21.1 10021881 - Infections and infestations 10069811 Respiratory syncytial virus bronchitis PT
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    21.1 10021881 - Infections and infestations 10035692 Pneumonia due to respiratory syncytial virus LLT
    21.1 10021881 - Infections and infestations 10067384 Respiratory syncytial virus pneumonitis LLT
    21.1 10021881 - Infections and infestations 10052200 Respiratory syncytial virus infection NOS LLT
    21.1 10021881 - Infections and infestations 10066741 Respiratory syncytial virus infection recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) NL (Ongoing) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000753-28 Sponsor Protocol Number: 212494 Start Date*: 2021-05-05
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase 3, randomized, placebo-controlled, observer-blind, multi-country study to demonstrate the efficacy of a single dose and annual revaccination of GSK’s RSVPreF3 OA investigational vaccine in ...
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10035732 Pneumonia respiratory syncytial viral PT
    21.1 10021881 - Infections and infestations 10038718 Respiratory syncytial virus bronchiolitis PT
    21.1 10021881 - Infections and infestations 10069811 Respiratory syncytial virus bronchitis PT
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    21.1 10021881 - Infections and infestations 10035692 Pneumonia due to respiratory syncytial virus LLT
    21.1 10021881 - Infections and infestations 10067384 Respiratory syncytial virus pneumonitis LLT
    21.1 10021881 - Infections and infestations 10052200 Respiratory syncytial virus infection NOS LLT
    21.1 10021881 - Infections and infestations 10066741 Respiratory syncytial virus infection recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing) DE (Ongoing) IT (Ongoing) SE (Prematurely Ended) HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-004003-41 Sponsor Protocol Number: 217354 Start Date*: 2022-02-11
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: A Phase III, randomized, open-label, active vaccine-controlled crossover study to evaluate the reactogenicity, safety and immune response of unadjuvanted RSV maternal vaccine in healthy non-pregnan...
    Medical condition: Healthy volunteers (prevention of RSV-associated lower respiratory tract illnesses (LRTIs))
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10035732 Pneumonia respiratory syncytial viral PT
    21.1 10021881 - Infections and infestations 10038718 Respiratory syncytial virus bronchiolitis PT
    21.1 10021881 - Infections and infestations 10066741 Respiratory syncytial virus infection recurrent LLT
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    21.1 10021881 - Infections and infestations 10052200 Respiratory syncytial virus infection NOS LLT
    21.1 10021881 - Infections and infestations 10067384 Respiratory syncytial virus pneumonitis LLT
    21.1 10021881 - Infections and infestations 10069811 Respiratory syncytial virus bronchitis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003600-55 Sponsor Protocol Number: ALN-RSV01-106 Start Date*: Information not available in EudraCT
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected ...
    Medical condition: Lung transplant patients with Human respiratory syncytial virus (RSV) infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052200 Respiratory syncytial virus infection NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004491-31 Sponsor Protocol Number: M12-420 Start Date*: 2015-02-03
    Sponsor Name:Abbott Japan Co., Ltd
    Full Title: Multi-center, Open-label, Uncontrolled Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less with Immunocompromised Medical Conditions
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-004582-27 Sponsor Protocol Number: RSV-MVA-013 Start Date*: 2018-07-23
    Sponsor Name:Bavarian Nordic A/S
    Full Title: A Phase 2a Randomized, Double-blinded, Placebo-controlled Trial to assess the Safety, Immunogenicity, and Efficacy of the recombinant MVA-BN-RSV Vaccine against Respiratory Syncytial Virus Infectio...
    Medical condition: Upper and lower respiratory tract infections caused by Respiratory Syncytical Virus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10039247 RSV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002651-24 Sponsor Protocol Number: MI-CP178 Start Date*: 2009-02-27
    Sponsor Name:MedImmune, LLC
    Full Title: A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuate...
    Medical condition: MEDI-534 is being investigated for the prevention of respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (hPIV3) infections and disease in young children and infants.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    14.1 10021881 - Infections and infestations 10061907 Parainfluenzae virus infection PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FI (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001135-12 Sponsor Protocol Number: 204812 Start Date*: 2016-10-27
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase II, randomised, observer-blind, controlled, multi-country study to rank different formulations of GSK Biologicals’ investigational RSV vaccine (GSK3003891A), based on immunogenicity, reacto...
    Medical condition: Respiratory Syncytial Virus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) EE (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-004248-11 Sponsor Protocol Number: Ahus-ATHENIAN Start Date*: 2021-11-10
    Sponsor Name:Akershus University Hospital
    Full Title: Antibiotic THErapy iN vIral Airway iNfections (ATHENIAN): An open labelled randomized controlled pragmatic trial to evaluate the efficacy and safety of discontinuing antibiotic therapy in adult pat...
    Medical condition: Patients with viral respiratory tract infection (influenza virus, parainfluenza virus, respiratory syncytial virus or human metapneumovirus)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001653-40 Sponsor Protocol Number: 64041575RSV2003 Start Date*: 2016-12-09
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered ALS-008176 Re...
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) SE (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003221-30 Sponsor Protocol Number: D5290C00008 Start Date*: 2021-10-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2, Open-label, Uncontrolled, Single-dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Occurrence of Antidrug Antibody for Nirsevimab in Immunocompromised Children ≤ ...
    Medical condition: RSV disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10066742 Respiratory syncytial virus infection prophylaxis LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-001714-96 Sponsor Protocol Number: R2222-RSV-1332 Start Date*: 2015-11-03
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in ...
    Medical condition: Medically attended respiratory syncytial virus infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10038717 Respiratory syncytial viral infections HLT
    Population Age: Preterm newborn infants, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed) HU (Completed) FI (Completed) BG (Completed) ES (Completed) CZ (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004137-21 Sponsor Protocol Number: 78591.041.21 Start Date*: 2021-10-28
    Sponsor Name:University Medical Center Utrecht
    Full Title: Effect of intranasal administration of palivizumab on experimental respiratory syncytial viral infection – a human challenge study
    Medical condition: respiratory syncytial virus infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003347-28 Sponsor Protocol Number: MK-1654-005 Start Date*: 2019-10-03
    Sponsor Name:Merck Sharp & Dohme Corp
    Full Title: A Phase 2a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Participants Inoculated with Experimental Respiratory Syncytial Virus.
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-002563-18 Sponsor Protocol Number: PC_RSV_003 Start Date*: 2017-10-09
    Sponsor Name:Pulmocide Ltd
    Full Title: A single-blind, placebo controlled, randomised study to evaluate antiviral activity and safety and pharmacokinetics of inhaled PC786 against respiratory syncytial virus (RSV) in healthy adult subje...
    Medical condition: Human Respiratory Syncytial Virus (RSV)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000109842 10070358 Human respiratory syncytial virus test positive LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001107-20 Sponsor Protocol Number: MDT-637-CP-201 Start Date*: 2013-08-02
    Sponsor Name:MicroDose Therapeutx, Inc., a wholly owned subsidiary of Teva Pharmaceuticals Industries, Ltd.
    Full Title: A Phase 2a Randomised, Double-Blind, Placebo-Controlled Repeat Dose Trial of the Activity of MDT-637 in Healthy Subjects Challenged with RSV-A (Memphis 37b)
    Medical condition: RSV Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10038717 Respiratory syncytial viral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-002848-22 Sponsor Protocol Number: MV-004 Start Date*: 2020-12-03
    Sponsor Name:Meissa Vaccines Inc.
    Full Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Prophylactic Efficacy of MV-012-968 Against Respiratory Syncytial Virus (RSV) Infection in the Virus Challe...
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-001355-40 Sponsor Protocol Number: 212171 Start Date*: 2021-02-23
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, randomized, double-blind, placebo-controlled multi-country study to demonstrate efficacy of a single dose of unadjuvanted RSV Maternal vaccine, administered IM to pregnant women 18 to ...
    Medical condition: Healthy Volunteers (prevention of lower respiratory tract illness)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed) FR (Completed) BE (Completed) IT (Ongoing) ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2020-001044-26 Sponsor Protocol Number: MB05-P-01-20 Start Date*: 2020-05-12
    Sponsor Name:mAbxience Research S.L.
    Full Title: A Double-Blind, Randomised, Placebo-Controlled Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated with Respiratory Syncytial Virus (RSV)
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-001641-79 Sponsor Protocol Number: 64041575RSV2001(ALS-8176-505) Start Date*: Information not available in EudraCT
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, Viral Kinetics, and Pharmacokinetics of Orally Administer...
    Medical condition: Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 04:55:05 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA